Type 2 11 Beta-hydroxysteroid Dehydrogenase in Foetal and Adult Life
Overview
Molecular Biology
Authors
Affiliations
Two isoforms of 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD) catalyse the interconversion of active cortisol to inactive cortisone; 11 beta-HSD1 is a low affinity, NADP(H)-dependent dehydrogenase/oxo-reductase, and 11 beta-HSD2 a high affinity, NAD-dependent dehydrogenase. Because of the importance of 11 beta-HSD in regulating corticosteroid hormone action, we have analysed the distribution of the 11 beta-HSD isoforms in human adult and foetal tissues (including placenta), and, in addition have performed a series of substrate specificity studies on the novel, kidney 11 beta-HSD2 isoform. Using an RT-PCR approach, we failed to detect 11 beta-HSD1 mRNA in any human mid-gestational foetal tissues. In contrast 11 beta-HSD2 mRNA was present in foetal lung, adrenal, colon and kidney. In adult tissues 11 beta-HSD2 gene expression was confined to the mineralocorticoid target tissues, kidney and colon, whilst 11 beta-HSD1 was expressed predominantly in glucocorticoid target tissues, liver, lung, pituitary and cerebellum. In human kidney homogenates, 11-hydroxylated progesterone derivatives, glycyrrhetinic acid, corticosterone and the "end products" cortisone and 11-dehydrocorticosterone were potent inhibitors of the NAD-dependent conversion of cortisol to cortisone. Finally high levels of 11 beta-HSD2 mRNA and activity were observed in term placentae, which correlated positively with foetal weight. The tissue-specific distribution of the 11 beta-HSD isoforms is in keeping with their differential roles, 11 beta-HSD1 regulating glucocorticoid hormone action and 11 beta-HSD2 mineralocorticoid hormone action. The correlation of 11 beta-HSD2 activity in the placenta with foetal weight suggests, in addition, a crucial role for this enzyme in foetal development, possibly in mediating ontogeny of the foetal hypothalamo-pituitary-adrenal axis.
Glucocorticoids and cognitive function: a walkthrough in endogenous and exogenous alterations.
De Alcubierre D, Ferrari D, Mauro G, Isidori A, Tomlinson J, Pofi R J Endocrinol Invest. 2023; 46(10):1961-1982.
PMID: 37058223 PMC: 10514174. DOI: 10.1007/s40618-023-02091-7.
Vant Westeinde A, Karlsson L, Messina V, Wallensteen L, Brosamle M, Dal Maso G Endocr Connect. 2023; 12(4).
PMID: 36752813 PMC: 10083667. DOI: 10.1530/EC-22-0400.
Vidal Jr M, Lintao R, Severino M, Tantengco O, Menon R Front Endocrinol (Lausanne). 2022; 13:1015622.
PMID: 36313741 PMC: 9606232. DOI: 10.3389/fendo.2022.1015622.
Pofi R, Tomlinson J Obstet Med. 2020; 13(2):62-69.
PMID: 32714437 PMC: 7359660. DOI: 10.1177/1753495X19847832.
Schiffer L, Barnard L, Baranowski E, Gilligan L, Taylor A, Arlt W J Steroid Biochem Mol Biol. 2019; 194:105439.
PMID: 31362062 PMC: 6857441. DOI: 10.1016/j.jsbmb.2019.105439.